Clinuvel Pharmaceuticals Limited

ASX:CUV.AX

14.98 (AUD) • At close September 18, 2024
Bedrijfsnaam Clinuvel Pharmaceuticals Limited
Symbool CUV.AX
Munteenheid AUD
Prijs 14.98
Beurswaarde 750,165,444
Dividendpercentage 0.33%
52-weken bereik 12.96 - 18.2
Industrie Biotechnology
Sector Healthcare
CEO Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA
Website https://www.clinuvel.com

An error occurred while fetching data.

Over Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria

Vergelijkbare Aandelen

PolyNovo Limited logo

PolyNovo Limited

PNV.AX

2.56 AUD

Integral Diagnostics Limited logo

Integral Diagnostics Limited

IDX.AX

2.59 AUD

Regis Healthcare Limited logo

Regis Healthcare Limited

REG.AX

5.74 AUD

Oceania Healthcare Limited logo

Oceania Healthcare Limited

OCA.AX

0.665 AUD

Mesoblast Limited logo

Mesoblast Limited

MSB.AX

0.92 AUD

Estia Health Limited logo

Estia Health Limited

EHE.AX

3.08 AUD

Mayne Pharma Group Limited logo

Mayne Pharma Group Limited

MYX.AX

4.5 AUD

Incannex Healthcare Limited logo

Incannex Healthcare Limited

IHL.AX

0.041 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)